Payment overview · 2025
General Payments
$394.87
14 reported records · 9 companies
Healthcare provider profile · identity verified
Brian D Wright, DO
Allopathic & Osteopathic Physicians|Internal Medicine · MYRTLE BEACH, SC · NPI 1164421525
Verified facts
What the public records show
CMS Open Payments records show Brian D Wright, DO received $394.87 in general payments during 2025 across 14 reported records.
Phathom Pharmaceuticals, Inc. accounted for 30.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.08 | 30.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.29 | 15.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.86 | 13.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.54 | 8.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $33.80 | 8.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.80 | 7.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.90 | 6.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.98 | 5.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.62 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $394.87 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $121.08 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.29 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $33.80 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.88 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.80 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 300 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 291 | 81 |
| Alprazolam | Alprazolam | 270 | 52 |
| Lisinopril | Lisinopril | 201 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 54 |
| Losartan Potassium | Losartan Potassium | 163 | 54 |
| Fluoxetine Hcl | Fluoxetine Hcl | 154 | 42 |
| Metformin Hcl | Metformin Hcl | 154 | 47 |
| Gabapentin | Gabapentin | 132 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 42 |
| Omeprazole | Omeprazole | 120 | 35 |
| Allopurinol | Allopurinol | 113 | 29 |
| Simvastatin | Simvastatin | 113 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 35 |
| Methylprednisolone | Methylprednisolone | 100 | 82 |
| Azithromycin | Azithromycin | 95 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 27 |
| Furosemide | Furosemide | 87 | 30 |
| Temazepam | Temazepam | 87 | 18 |
| Atenolol | Atenolol | 84 | 22 |
| Eliquis | Apixaban | 83 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 15 |
| Meloxicam | Meloxicam | 74 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 16 |
| Synthroid | Levothyroxine Sodium | 66 | 19 |
| Trazodone Hcl | Trazodone Hcl | 57 | 17 |
| Ezetimibe | Ezetimibe | 56 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 43 |
| Sertraline Hcl | Sertraline Hcl | 47 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 18 |
| Tramadol Hcl | Tramadol Hcl | 44 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 12 |
| Carvedilol | Carvedilol | 39 | 13 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | 12 |
| Celecoxib | Celecoxib | 37 | 11 |
| Farxiga | Dapagliflozin Propanediol | 37 | 13 |
| Amoxicillin | Amoxicillin | 35 | 24 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 17 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $394.87 · 14 records | Phathom Pharmaceuticals, Inc. | Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, Korlym, Ozempic, Rybelsus, SYNTHROID, UBRELVY, VOQUEZNA, Veozah, WaveWriter Alpha Prime 16, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error